Roche’s gantenerumab fails in Phase II/III inherited Alzheimer’s trial
Roche’s gantenerumab is being developed to treat patients with Alzheimer’s. Credit: F. Hoffmann-La Roche Ltd.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more